Equillium to Present Translational Preclinical Data Demonstrating Increased Survival and Decreased Disease Severity in Models of Graft-Versus-Host Disease Treated with Itolizumab at the Transplantation & Cellular Therapy Meetings of ASTCT & CIBMTR
January 29, 2020 16:07 ET
|
Equillium
LA JOLLA, Calif., Jan. 29, 2020 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging deep understanding of immunobiology to develop products to treat...
Equillium to Present Translational Data on Itolizumab for Acute Graft-Versus-Host Disease at 61st American Society of Hematology (ASH) Annual Meeting and Exposition
November 26, 2019 16:07 ET
|
Equillium
LA JOLLA, Calif., Nov. 26, 2019 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging deep understanding of immunobiology to develop products to treat...
Equillium to Present at Investor Conferences in November 2019
November 07, 2019 16:07 ET
|
Equillium
LA JOLLA, Calif., Nov. 07, 2019 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging deep understanding of immunobiology to develop products to treat...
Equillium Announces Initiation of the EQUALISE Phase 1b Clinical Trial of Itolizumab for Patients with Lupus Nephritis and Provides Business Update
October 01, 2019 16:05 ET
|
Equillium
Company secures up to $20 million debt facility with Silicon Valley Bank and Oxford Finance LLC Company receives exclusive rights to negotiate licensing rights to develop and commercialize itolizumab...
Bellicum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
August 30, 2019 16:08 ET
|
Bellicum Pharmaceuticals, Inc.
HOUSTON, Aug. 30, 2019 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers and orphan inherited blood...
Bellicum Pharmaceuticals to Participate in Three Healthcare Investor Conferences during September
August 28, 2019 16:05 ET
|
Bellicum Pharmaceuticals, Inc.
HOUSTON, Aug. 28, 2019 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers and orphan inherited blood...
Bellicum Pharmaceuticals Announces Aggregate Gross Proceeds of $69.6 Million from $139.6 Million Public Offering and Private Placement
August 21, 2019 16:05 ET
|
Bellicum Pharmaceuticals, Inc.
HOUSTON, Aug. 21, 2019 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (Nasdaq: BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers and orphan inherited blood...
Bellicum Pharmaceuticals Announces Proposed $53.0 Million Public Offering of Preferred Stock and Warrants with Concurrent Private Placement
August 15, 2019 17:37 ET
|
Bellicum Pharmaceuticals, Inc.
HOUSTON, Aug. 15, 2019 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (Nasdaq: BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers and orphan inherited blood...
Bellicum Pharmaceuticals Reports Second Quarter 2019 Financial Results and Provides Operational Update
August 05, 2019 16:15 ET
|
Bellicum Pharmaceuticals, Inc.
Interim safety and activity data for BPX-601 presented at American Society of Clinical Oncology (ASCO) Annual Meeting Rivo-celTM achieved primary endpoint in BP-004 European registrational trial ...
Bellicum Pharmaceuticals Announces Rivo-cel™ Achieves Primary Endpoint in Pediatric Registrational Trial
July 08, 2019 08:00 ET
|
Bellicum Pharmaceuticals, Inc.
Primary endpoint of event free survival (EFS) rate at 180 days of 90.9 percent reported for rivo‑cel in BP-004 European registrational trial Investigational trial results support potential that...